Focus: Daiichi Sankyo is a public biotechnology company headquartered in Shanghai, specializing in small-molecule oncology, cardiovascular, and metabolic disease therapeutics. The company operates at scale with significant market presence anchored by blockbuster ADC franchises.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Daiichi Sankyo to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Blockbuster ADC generating 55% of company revenue with expanding multi-indication franchise and strong clinical momentum in solid tumors.
Help build intelligence for Daiichi Sankyo
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Daiichi Sankyo's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Anticoagulant facing patent expiration within 4 years, representing material cliff risk and restructuring catalyst for cardiovascular business unit.
Orphan-focused kinase inhibitor with extended patent protection through 2038, providing long-tail revenue stability for specialty oncology.
FLT3 inhibitor in growth phase with Phase 2 trials ongoing in pediatric AML and Phase 3 enrollment, indicating expansion potential.
Trop-2 directed ADC recently launched for EGFR-mutant lung cancer with Phase 3 trials ongoing, representing major pipeline-to-revenue transition.
4 discontinued, 0 duplicate formulations not shown
Daiichi Sankyo Co Ltd stock (JP3475350009): FDA approval for Enhertu adds new US oncology momentum - AD HOC NEWS
Daiichi Sankyo Co Ltd stock (JP3475350009): FDA approval for Enhertu adds new US oncology momentum AD HOC NEWS
Daiichi Sankyo Co Ltd stock (JP3475350009): FDA approval for Enhertu highlights US oncology growth - AD HOC NEWS
Daiichi Sankyo Co Ltd stock (JP3475350009): FDA approval for Enhertu highlights US oncology growth AD HOC NEWS
Daiichi Sankyo's Antibody-Drug Conjugate Platform Shines but Faces Increasing Competition - Morningstar
Daiichi Sankyo's Antibody-Drug Conjugate Platform Shines but Faces Increasing Competition Morningstar
Daiichi Sankyo Reports Billion-Dollar Revenue Amid Heavy One-Off Costs - streamlinefeed.co.ke
Daiichi Sankyo Reports Billion-Dollar Revenue Amid Heavy One-Off Costs streamlinefeed.co.ke
Daiichi Sankyo stock (JP3475350009): oncology surge drives FY2025 growth, five-year plan targets top - AD HOC NEWS
Daiichi Sankyo stock (JP3475350009): oncology surge drives FY2025 growth, five-year plan targets top AD HOC NEWS
8-K Filing: Metagenomi Therapeutics, Inc. (MGX) (CIK 0001785279) — EX-99.1
EX-99.1
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
An Expert Consensus-Based Review of Considerations for Developing a Quality Management System Framework for Studies Utilising Secondary Data for Real-World Evidence Generation.
Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial Designs.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo